Propafenone (HCl)

Propafenone (HCl) is antiarrhythmic agent. its spectrum of action is very similar to that of quinidine. its potency as a sodium channel blocker is similar to that of flecainide. It has some structural similarities to propranolol and possess weak β-adrenergic blocking activity.

Brands
Adult Dose
Dose: 2.14 to 4.29 mg/kg
Single Dose: 3.2 (3.215)
Frequency: 8 hourly
Route: PO
Instructions: -
Neonatal
Paedriatic
Characteristics
Propafenone (HCl) also known as Fenopraine HCl. . It is of Synthetic origin and belongs to Propiophenone. It belongs to Na-Channel Antiarrhythmic antagonist pharmacological group on the basis of mechanism of action and also classified in Anti arrhythmic agents pharmacological group.The Molecular Weight of Propafenone (HCl) is 377.90. Its pKa is 8.8.
Contraindications
Propafenone (HCl) is contraindicated in conditions like Cardiogenic shock,Congestive heart failure,Hypotension,Obstructive airway disease.
Effects
Propafenone (HCl) produces potentially life-threatening effects which include Bradycardia, Hypotension. which are responsible for the discontinuation of Propafenone (HCl) therapy.The symptomatic adverse reactions produced by Propafenone (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Nausea, Diarrhea, Constipation, Visual disorders, Dry mouth, Blurred vision, VertigoX, Taste disturbance.
Indications
Propafenone (HCl) is primarily indicated in conditions like Cardiac arrhythmia, Supraventricular tachycardia, Ventricular arrhythmias, Ventricular arrhythmias; Paroxysmal supraventricular tachyarrhythmias.
Interactions
Propafenone (HCl) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAmiodarone (HCl)Increased myocardial depression and increased risk of ventricular arrhythmias when amiodarone given with other antiarrhythmics (e.g Propafenon). ADVICE: Avoid concomitant use or only undertaken with caution and appropriate monitoring.AmprenavirAmprenavir possibly increases plasma concentration of Propafenone; increased risk of ventricular arrhythmias. ADVICE: Avoid concomitant use.MajorCimetidine (HCl)Desipramine (HCl)DextromethorphanDigoxinPropafenone may increase the serum concentration of Digoxin.ModerateMonitor increased serum concentrations/toxic effects of Digoxin if propafenone is initiated/dose increased, or decreased serum concentrations/effects if propafenone is discontinued/dose decreased.Distigmine (Br)LignocaineMetoprolol (Tartrate)Combined use of both drugs increases Plasma conc of former agentNelfinavirParoxetinePyridostigmine (Br)QuinidineRifampicinRitonavirRivastigmineTheophyllineVORICONAZOLEAdditive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongationWarfarin (Na) These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
Risks
Drug should not be given to Pregnant Mothers, Cardiac / Hypertensive Patients, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Tab Store Below 40°C. Protect from Sunlight and Moisture.
Warnings
Propafenone should be used only when clearly needed during pregnancy.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.